Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 96, Issue 11, Pages 1472-1480Publisher
WILEY
DOI: 10.1002/ajh.26332
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC) 51000 call Metastatic disease: the key unmet need in oncology [21267]
- Bando Ricerca Finalizzata Ministero della Salute [RF-2016-02362930]
Ask authors/readers for more resources
This study identified predictive factors for inferior myelofibrosis-free survival in patients with WHO-defined essential thrombocythemia, and developed a molecular risk category based on JAK2V617F, CALR, and MPL mutations. High molecular risk patients had significantly higher rates of fibrotic transformation, providing useful risk signals for patient monitoring and counseling.
The current retrospective study involving a total of 1607 patients was designed to identify clinical and molecular variables that were predictive of inferior myelofibrosis-free survival (MFS) in WHO-defined essential thrombocythemia (ET), utilizing three independent patient cohorts: University of Florence, Italy (n = 718); Mayo Clinic, USA (n = 479) and Policlinico Gemelli, Catholic University, Rome, Italy (n = 410). The Florence patient cohort was first examined to identify independent risk factors for MFS, which included age > 60 years (HR 2.5, 95% CI 1.3-4.9), male sex (2.1, 1.2-3.9), palpable splenomegaly (2.1, 1.2-3.9), CALR 1/1-like or MPL mutation (3.4, 1.9-6.1) and JAK2V617F variant allele frequency > 35% (4.2, 1.6-10.8). Subsequently, an operational molecular risk category was developed and validated in the other two cohorts from Mayo Clinic and Rome: high molecular risk category included patients with JAK2V617F VAF >35%, CALR type 1/1-like or MPL mutations; all other driver mutation profiles were assigned to low molecular risk category. The former, compared to the latter molecular risk category, displayed significantly higher risk of fibrotic transformation: Florence cohort with respective fibrotic transformation risk rates of 8% vs. 1.2% at 10 years and 33% vs. 8% at 20 years (p < 0.001; HR 6.1; 95% CI 3.2-11.7); Mayo Cohort, 16% vs. 7% at 10 years and 44% vs. 25% at 20 years (p < 0.001; HR 2.5; 95% CI 1.6-4.1); and Rome cohort 7.8% vs. 4.6% at 10 years and 31.2% vs. 7.1% at 20 years (p = 0.007, HR 2.7; 95% CI 1.3-5.8). The present study provides practically useful risk signals for fibrotic transformation in ET and facilitates identification of patients who require close monitoring and appropriate counseling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available